{
    "tag": [
        "compiled"
    ],
    "id": "ocds-b5fd17-026d485d-1c56-4c08-bef2-c3bd718da193-2018-12-10T16:01:03Z",
    "date": "2018-12-10T16:01:03Z",
    "ocid": "ocds-b5fd17-026d485d-1c56-4c08-bef2-c3bd718da193",
    "language": "en",
    "initiationType": "tender",
    "title": "Clone Lentiviral Particles or equivalent",
    "planning": {
        "milestones": [
            {
                "id": "1",
                "title": "Engagement end date",
                "type": "engagement",
                "dueDate": "2018-12-28T23:59:59Z"
            }
        ],
        "documents": [
            {
                "id": "1",
                "documentType": "marketEngagementNotice",
                "description": "Early engagement notice on Contracts Finder",
                "url": "https://www.contractsfinder.service.gov.uk/Notice/43450eb3-4284-4749-a2ac-0573f7dbdce3",
                "datePublished": "2018-12-10T16:01:03Z",
                "format": "text/html",
                "language": "en"
            }
        ]
    },
    "tender": {
        "id": "CLP or equivalent",
        "title": "Clone Lentiviral Particles or equivalent",
        "description": "The Agency requires to purchase specified Clone Lentiviral Particles or equivalent. An over view of the requirement is: \"The project is based on genetic modification of macrophage cell lines with two tagged genes with lentiviral particles such as - 1. Sp110 (NM_175397) Mouse Tagged ORF Clone Lentiviral Particle and 2, Arl8b (NM_026011) Mouse Tagged ORF Clone Lentiviral Particle. We would like to perform a proof of concept theory in-vitro for pathogens of our interest. Ideally, we are planning to order reagents middle of January 2018 and in-vitro work would last for 2-3 months. If the proof-of-concept study looks promising we are planning to order more plasmids and perform more in-vitro experiments.\" Potential suppliers if they feel they can meet the requirement should email Nawaz.habib@nibsc.org to register an interest. If no submissions of potential interest are received by close of play 28 December 2018, it is then intended to perform a direct award without competition to the sole supplier we believe can deliver this requirement.",
        "status": "planning",
        "classification": {
            "scheme": "CPV",
            "id": "33696500",
            "description": "Laboratory reagents"
        },
        "additionalClassifications": [
            {
                "scheme": "CPV",
                "id": "33698100",
                "description": "Microbiological cultures"
            },
            {
                "scheme": "CPV",
                "id": "38970000",
                "description": "Research, testing and scientific technical simulator"
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "East of England",
                        "countryName": "United Kingdom"
                    }
                ]
            }
        ],
        "suitability": {
            "sme": true,
            "vcse": false
        }
    },
    "parties": [
        {
            "id": "GB-GOR-EA63",
            "name": "Medicines and Healthcare Products Regulatory Agency",
            "identifier": {
                "legalName": "Medicines and Healthcare Products Regulatory Agency",
                "scheme": "GB-GOR",
                "id": "EA63"
            },
            "address": {
                "streetAddress": "Blanche Lane, ,, South Mimms,",
                "locality": "Potters Bar, Hertfordshire",
                "postalCode": "EN6 3QG",
                "countryName": "England"
            },
            "contactPoint": {
                "name": "Nawaz Habib",
                "email": "nawaz.habib@nibsc.org",
                "telephone": "01707641212"
            },
            "roles": [
                "buyer"
            ]
        }
    ],
    "buyer": {
        "id": "GB-GOR-EA63",
        "name": "Medicines and Healthcare Products Regulatory Agency"
    }
}